x
Filter:
Filters applied
- Immunology
- Cole, David KRemove Cole, David K filter
- Fuller, AnnaRemove Fuller, Anna filter
Author
- Dolton, Garry2
- Lloyd, Angharad2
- Rizkallah, Pierre J2
- Sewell, Andrew K2
- Attaf, Meriem1
- Beck, Konrad1
- Bianchi, Valentina1
- Bulek, Anna1
- Bulek, Anna M1
- Clement, Mathew1
- Crowther, Michael D1
- Ekeruche-Makinde, Julia1
- Laugel, Bruno1
- Miles, John J1
- Schauenburg, Andrea J1
- van den Berg, Hugo A1
- Wall, Aaron1
- Wooldridge, Linda1
Immunology
2 Results
- ImmunologyOpen Access
Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse Transcriptase
Journal of Biological ChemistryVol. 292Issue 3p802–813Published online: November 30, 2016- David K. Cole
- Hugo A. van den Berg
- Angharad Lloyd
- Michael D. Crowther
- Konrad Beck
- Julia Ekeruche-Makinde
- and others
Cited in Scopus: 17T-cell cross-reactivity is essential for effective immune surveillance but has also been implicated as a pathway to autoimmunity. Previous studies have demonstrated that T-cell receptors (TCRs) that focus on a minimal motif within the peptide are able to facilitate a high level of T-cell cross-reactivity. However, the structural database shows that most TCRs exhibit less focused antigen binding involving contact with more peptide residues. To further explore the structural features that allow the clonally expressed TCR to functionally engage with multiple peptide-major histocompatibility complexes (pMHCs), we examined the ILA1 CD8+ T-cell clone that responds to a peptide sequence derived from human telomerase reverse transcriptase. - ImmunologyOpen Access
A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen
Journal of Biological ChemistryVol. 291Issue 17p8951–8959Published online: February 25, 2016- Valentina Bianchi
- Anna Bulek
- Anna Fuller
- Angharad Lloyd
- Meriem Attaf
- Pierre J. Rizkallah
- and others
Cited in Scopus: 23Human CD8+ cytotoxic T lymphocytes can mediate tumor regression in melanoma through the specific recognition of HLA-restricted peptides. Because of the relatively weak affinity of most anti-cancer T-cell receptors (TCRs), there is growing emphasis on immunizing melanoma patients with altered peptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward these self-antigens. However, previous studies have shown that these immunogenic designer peptides are not always effective.